Despite strategic announcements, the significant revenue decline and widening losses outweigh positive developments. Monitor for signs of margin improvement and cost control in upcoming quarters, particularly whether SG&A expenses stabilize now that IPO-related costs are behind the company.
Price Chart
Executive Summary
Callan JMB reported full-year 2025 financial results with revenue declining 12.7% year-over-year to $5.72 million and net loss widening to $7.97 million from $2.29 million in 2024. Despite the deterioration in financials, the company highlighted strategic growth initiatives including a partnership with biotech firm Attune, expansion into India, and new government contracts.
Key Financial Metrics
Key Facts
- Revenue for FY 2025 was $5.72 million, down from $6.56 million in FY 2024 (-12.7% YoY)
- Net loss widened to $7.97 million in 2025 from $2.29 million in 2024
- SG&A expenses increased to $8.6 million from $4.8 million due to public company costs
- Signed agreement with Attune Biotech to oversee manufacturing of clinical and commercial assets
- Cash and cash equivalents ended at $2.13 million, up slightly from $2.10 million
Financial Impact
Revenue down $840K YoY, net loss increased by $5.67M, SG&A up $3.76M
Risk Factors
- Continued decline in core emergency preparedness revenue
- High SG&A spend relative to revenue base threatens sustainability
- Execution risk on new strategic initiatives in biotech and India
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014140 |
| Document: form8-k.htm | 0001493152-26-014140 |
| Document: 0001493152-26-014140-index-headers.html | 0001493152-26-014140 |
| Document: 0001493152-26-014140-index.html | 0001493152-26-014140 |
| Document: 0001493152-26-014140.txt | 0001493152-26-014140 |
| 8-K Data (Synthetic) | 0001493152-26-014140 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $1.92 $0.4787 | ▼ −75.07% | ▼ −74.92% | $0.4900 (−74.48%) |
Oct 16, 2026 10d ago | 8-K | $1.92 $0.4787 | ▲ +75.07% | ▲ +74.92% | $0.4900 (+74.48%) |
Aug 27, 2026 8w ago | Press Release | $2.20 $2.11 | ▼ −4.09% | ▼ −4.36% | $0.4900 (−77.73%) |
Aug 24, 2026 9w ago | 8-K | $2.27 $2.15 | ▼ −5.29% | ▼ −5.76% | $0.4900 (−78.41%) |
Aug 20, 2026 9w ago | 8-K | $2.36 $2.20 | ▲ +6.58% | ▲ +7.70% | $0.4900 (+79.19%) |
Jul 16, 2026 14w ago | Press Release | $0.8610 $2.35 | ▲ +172.94% | ▲ +174.61% | $0.4900 (−43.09%) |
Jul 8, 2026 15w ago | Press Release | $0.7531 $0.8610 | ▲ +14.33% | ▲ +14.46% | $0.4900 (−34.94%) |
Jul 2, 2026 16w ago | 8-K | $0.8160 $0.7531 | ▲ +7.71% | ▲ +8.64% | $0.4900 (+39.95%) |
Jun 11, 2026 19w ago | 8-K | $0.8212 $0.7179 | ▼ −12.58% | ▼ −13.25% | $0.4900 (−40.33%) |
Jun 8, 2026 20w ago | EFFECT | $0.7670 $0.7020 | ▲ +8.47% | ▲ +10.59% | $0.4900 (+36.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers